NHLBI Next Gen – Sickle Cell Anemia (Dr. Steinberg, Dr. Mostoslavsky, Dr. Murphy, Boston University and Boston Medical Center's Center for Regenerative Medicine)


About the Steinberg, Mostoslavsky, Murphy Next Gen Cell Lines 


This collection, from Dr. Martin Steinberg, Dr. Gustavo Mostoslavsky, and Dr. George Murphy (Boston University and Boston Medical Center's Center for Regenerative Medicine), used erythroid cells from patient-specific iPSCs to study genetic factors modulating the severity of sickle cell anemia and its responsiveness to treatment.  This study was largely centered on this feature of the disease where the quantitative trait loci evaluated affect fetal hemoglobin (HbF) expression. 

The iPS cell lines in this collection were banked and characterized in the laboratory of Dr. Gustavo Mostoslavsky, Boston University.

This collection contains over 40 cell lines.  Individuals giving rise to iPSC lines were of African American or Arab descent.  Disease states for the subjects include sickle cell anemia as well as no reported diagnoses.  Age of donors range from 3-45 years. 

For more information on Boston University and Boston Medical Center's Center for Regenerative Medicine, visit http://www.bu.edu/dbin/stemcells.

The publication describing this collection of Sickle Cell Anemia iPSCs may be found here.

Additional information regarding relationships can be found here.

About the Next Generation Genetic Association Studies (Next Gen) Program         

These cell lines were created as Next Generation Genetic Association Studies (Next Gen) Program, which was a five-year, $80 million program to investigate functional genetic variation in humans by assessing cellular profiles that are surrogates for disease phenotypes. To achieve this, researchers from multiple institutions across the U.S. were awarded grants to derive iPS cell lines from more than 1,500 individuals representing various conditions as well as healthy controls for use in functional genomic (‘disease in a dish’) research. This extensive panel includes a diverse set of age, gender and ethnic backgrounds, and therefore will be an invaluable tool for evaluations across demographics. Further enhancing the utility of these cell lines are data sets such as phenotyping, GWAS, genome sequencing, gene expression and -omics analyses (e.g., lipidomic, proteomic, methylomic) that will be made available with the cell lines.
Cell Lines 42 Cell Lines
Show records
<
1
2
3
4
5
Go to page Go
Cell Line Cell Line Alias Cell Type Disease Genetic Alteration/Mutation Sex Age at Collection Ethnicity Genetically Related Cell Lines dbGaP Data
CREM001i-bBU1C2 bBU1C2 Human iPS None reported    Male 42 Years Caucasian  No Yes
CREM002i-BU2C10 BU2-15-Cre10 Human iPS None reported    Male 45 Years Caucasian  No Yes
CREM003i-BU3C2 BU3-10-Cre02 Human iPS None reported    Male 40 Years Caucasian  No Yes
CREM004i-SS2-1 SS2-1 Human iPS Sickle cell anemia SS  HBB(E6V)  Female 32 Years African American  No Yes
CREM006i-SS4-1 SS4-1 Human iPS Sickle cell anemia SS  HBB(E6V)  Male 30 Years African American  No Yes
CREM007i-SS5-1 SS5-1 Human iPS Sickle cell anemia SS  HBB(E6V)  Male 32 Years African American  No Yes
CREM008i-SS6-1 SS6-1 Human iPS Sickle cell anemia SS  HBB(E6V)  Female 24 Years African American  Yes Yes
CREM009i-SS8-2 SS8-2 Human iPS Sickle cell anemia SS  HBB(E6V)  Female 31 Years African American  No Yes
CREM010i-SS9-1 SS9-1 Human iPS Sickle cell anemia SS  HBB(E6V)  Female 29 Years African American  No Yes
CREM012i-SS13-1 SS13-1 Human iPS Sickle cell anemia SS  HBB(E6V)  Female 25 Years African American  No Yes
Cell Lines 42 Cell Lines
Show records
<
1
2
3
4
5
Go to page Go